secwatch.observer — SEC 8-K summary
======================================

Issuer:     Indaptus Therapeutics, Inc. (INDP)
CIK:        0001857044
Form:       8-K
Filed at:   2024-03-04T23:59:59+00:00
Accession:  0001493152-24-008670
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Indaptus reports positive Phase 1 results for Decoy20; moves to multi-dose trial
--------------------------------------------------------------------------------

- Second cohort of Phase 1 INDP-D101 trial showed broad immune response consistent with first cohort.
- Independent Safety Review Committee recommended continuing to multiple doses of Decoy20.
- Company has started screening patients for multi-dose safety and efficacy across multiple cancer types.
- Animal models demonstrated Decoy20 safety in several multiple-dose schedules.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1857044/000149315224008670/0001493152-24-008670-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1857044/000149315224008670/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-008670

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer